Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radioimmunotherapy Combination Patterns in Metastatic NSCLC
NCT06947694Phase 2Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Xinqiao Hospital. Primary endpoint: Remission rate of abscopal lesions at 2 years. Started Jul 2025; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06947694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947694.